James Williams
Co-Founder and and Investment Director @ Yuuwa Capital
Perth, Australia
James Williams is a seed investor at Yuuwa Capital in Perth focused on Medical and Health Care. James Williams has broad experience covering executive management of public and private companies, establishment, resourcing and financing start-up companies and hands-on research in molecular and cell biology.James has been CEO of private and listed medical device companies Argus Biomedical Pty Ltd and Resonance Health Ltd (spin-out companiesfrom the Lions Eye Institute and UWA respectively); in both cases he oversaw regulatory approvals and market launch of first products. He co-founded, is the former CEO and remains a Director of GPCR drug discovery company Dimerix Biosciences Pty Ltd (a spin-out from the Western Australian Institute for Medical Research). In 2003, James conceived the business concept behind UWA spin-out iCeutica. He held various Executive and non-Executive roles with iCeutica until the company was sold in April 2011 for 10 times return on investment at the time of first financing.Prior to becoming involved in technology commercialisation, James was a Senior Research Officer at WAIMR where he was researching the molecular and cellular biology of cancer. He has numerous publications in leading international journals and is named as inventor on patents covering a range of disciplines that are being prosecuted as part of Australian company’s technology portfolios. Noteworthy examples are patents describing iCeutica’s core technology for producing nano drugs, and the HLS5 tumour suppressor gene he cloned during post-doctoral studies and which is being commercialised by ASX-listed Biopharmica Ltd.James is a Director of Yuuwa investee companies AdAlta Pty Ltd and GordianTec Pty Ltd ,and an observer to the Board of FilterSquad Pty Ltd. He is a member of the “Panel of Experts” for the University of Western Australia’s Pathfinder Fund, a Director of Linear Clinical Research Ltd, an early stage clinical trials unit based in Perth, and a previous member of the Development Grant Review Panel for the National Health and Medical Research Council (NHMRC). James completed his Honours Degree in Biochemistry at Aberdeen University, Doctorate in Medicine at the University of Melbourne and Masters of Business Administration at the University of Western Australia.James is a co-founder and Investment Director of Yuuwa Capital. He has a broad interest in the successful commercialisation of early stage technologies, with a particular focus on those stemming from the Life Sciences.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 78%
Last updated:
For AI agents: llms.txt
Industries James Williams invests in
Stages James Williams invests in
Countries James Williams invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 4 (44%)
- Health Care 4 (44%)
- Biotechnology 4 (44%)
- iOS 1 (11%)
- Apps 1 (11%)
Stage
- Seed 4 (44%)
- Series A 2 (22%)
- Series B 1 (11%)
- Venture - Series Unknown 1 (11%)
Country
- Australia 6 (67%)
- France 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Nexgen is an emerging plant trait company delivering non-GM solutions for a range of pathogens, production traits and consumer traits. Our solutions help agriculture-dependent communities around the world improve returns and respond rapidly to emerging opportunities and challenges. The proprietary transformation technique is developing crops thatare virus-resistant; fungal-resistant; salt-tolerant; high in anthocyanin content; and aromatic.These solutions are developing the next generation of globally valued crops for food, fibre, energy and ornamentation. | $2.2M / Venture - Series Unknown / Aug 23, 2018 | ||
| Nexgen is an emerging plant trait company delivering non-GM solutions for a range of pathogens, production traits and consumer traits. Our solutions help agriculture-dependent communities around the world improve returns and respond rapidly to emerging opportunities and challenges. The proprietary transformation technique is developing crops thatare virus-resistant; fungal-resistant; salt-tolerant; high in anthocyanin content; and aromatic.These solutions are developing the next generation of globally valued crops for food, fibre, energy and ornamentation. | $1.8M / Series A / Sep 03, 2013 | ||
| Eridan Technology is a Norway-based company that commercializes nanoparticle technology for drug delivery therapies. It is headquartered in Aust-Agder, Norway. | $135K / Seed / Apr 05, 2013 | ||
| PolyActiva has developed proprietary drug-polymer conjugate technology that enables site-specific drug delivery from medical device components such as ocular implants, intra-articular gel implants, and drug-eluting fibers. | $6.4M / Series B / Feb 19, 2013 | ||
| Filter Squad makes the Discovr series of apps: Discovr Music, Discovr Apps, Discovr Movies. Number 1 app in 52 countries including US, Japan, Australia, and across Europe. More than 1.5 million downloads. Featured worldwide by Apple. Listed as one of Billboard 10 Top Music Startups 2011. Winner of Tech23 Greatest Potential Award 2011. Winner ofMIDEM Best Consumer Startup 2011. Featured in the Wall Street Journal, Techcrunch, Mashable, Read Write Web, Gizmodo, Lifehacker, Scobleizer, Macworld, Wired Magazine. | $718K / Seed / Oct 26, 2011 | ||
| Gordiantec is a start-up company and was founded on 25 August 2011. It is a private, unlisted Australian company. The company is funded by capital group Yuuwa Capital LP. Gordiantec is developing applications of a technology implemented by personnel at the University of Western Australia / Western Australian Institute for Medical Research(WAIMR).Gordiantec is validating algorithms for SNP data identification that are associated with disease outcomes and/or population sub-types. Gordiantec has filed or is filing patent applications for diagnostics in areas including diabetes and cancer. It is expanding application of its approach to new diseases. | $808K / Seed / Oct 04, 2011 | ||
| Oz Sonotek is an Australian-incorporated developer of innovative medical technologies designed to better manage ultrasound energy during cataract surgery (phaco-emulsification).The company was founded by Dr Nigel Morlet, eye surgeon and researcher, who has successfully designed and commercialized previous ophthalmic devices, and who haspublished widely in journals such as New England Journal of Medicine. He has engaged an experienced leadership team that have a successful track record. They are experienced in research, development, commercialization, regulatory, IP protection, sales, distribution, and crafting revenue licensing partnerships with major players.Our principal research themes involve design and test of more efficient needle tips for phacoemulsification, which will be followed by next generation ultrasonic hand-pieces and energy management software improvements. The first product will shortly be introduced into global cataract surgery markets, with highly pedigreed partners.The company now has venture capital shareholders, and in 2012, the won a significant, competitive cash innovation grant from the State of Western Australia.We presented our clinical outcomes at major eye care meetings including Meeting of the American Society of Cataract & Refractive Surgery in 2011 and 2012 | $673K / Seed / Apr 16, 2011 | ||
| Filter Squad makes the Discovr series of apps: Discovr Music, Discovr Apps, Discovr Movies. Number 1 app in 52 countries including US, Japan, Australia, and across Europe. More than 1.5 million downloads. Featured worldwide by Apple. Listed as one of Billboard 10 Top Music Startups 2011. Winner of Tech23 Greatest Potential Award 2011. Winner ofMIDEM Best Consumer Startup 2011. Featured in the Wall Street Journal, Techcrunch, Mashable, Read Write Web, Gizmodo, Lifehacker, Scobleizer, Macworld, Wired Magazine. | $131K / Seed / Jan 16, 2011 | ||
| AdAlta Pty Ltd (AdAlta) is a Melbourne based biotech company discovering and developing protein based therapeutics. AdAlta aims to provide an alternative approach to drug discovery by finding novel shark antibody or i-body drug candidate agents for various disease conditions. AdAlta has significant expertise and proprietary libraries that willenable the discovery and identification of lead candidates. AdAlta can rapidly identify high quality binders from it's i-body or shark antibody libraries.A particular focus is given to the discovery of protein therapeutics against non-traditional antibody targets, such as complex membrane spanning proteins. AdAlta’s proprietary discovery technology is particularly well suited to approach this class of drug-targets that formerly was inaccessible to most protein-binder platforms.AdAlta is focused on building a pipeline of therapeutics against clinically validated targets that demonstrate significant advantages over currently marketed protein products. AdAlta also conducts collaborative and contract research. Our approach allows us to leverage the diversity of the AdAlta libraries and apply it to collaborators targets. AdAlta has a number of collaborations with research organization, biotech and pharma companies. | $2M / Series A / Jan 05, 2011 |
Co-Investors
About Yuuwa Capital
Yuuwa Capital is a $40M early-stage venture capital firm based in Perth, Western Australia. They are actively seeking outstanding investment opportunities where Yuuwa can provide both capital and expertise to help founders, management and early investors to turn good ideas into great companies.
Yuuwa Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
James Williams
Co-Founder and and Investment Director
|
|||
Liddy McCall
Co-Founder and Investment Director
|
|||
Matthew Macfarlane
Co-Founder and Investment Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does James Williams invest in?
James Williams invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed and Series A stage. Most of the 9 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact James Williams?
Public channels for James Williams include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did James Williams last invest?
The most recent investment recorded for James Williams closed in Aug 2018. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
